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Protein synthesis is essential for cell growth, proliferation, and sur-
vival. Protein synthesis is a tightly regulated process that involves
multiple mechanisms. Deregulation of protein synthesis is considered
as a key factor in the development and progression of a number of
diseases, such as cancer. Here we show that the dynamic modification
of proteins by O-linked β-N-acetyl-glucosamine (O-GlcNAcylation) reg-
ulates translation initiation by modifying core initiation factors eIF4A
and eIF4G, respectively. Mechanistically, site-specific O-GlcNAcylation
of eIF4A on Ser322/323 disrupts the formation of the translation ini-
tiation complex by perturbing its interaction with eIF4G. In addition,
O-GlcNAcylation inhibits the duplex unwinding activity of eIF4A, lead-
ing to impaired protein synthesis, and decreased cell proliferation. In
contrast, site-specific O-GlcNAcylation of eIF4G on Ser61 promotes its
interaction with poly(A)-binding protein (PABP) and poly(A) mRNA.
Depletion of eIF4G O-GlcNAcylation results in inhibition of protein
synthesis, cell proliferation, and soft agar colony formation. The
differential glycosylation of eIF4A and eIF4G appears to be regu-
lated in the initiation complex to fine-tune protein synthesis. Our
study thus expands the current understanding of protein synthesis,
and adds another dimension of complexity to translational control
of cellular proteins.
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Protein synthesis is a tightly regulated process and is essentialfor cell growth and proliferation. Protein synthesis contains
three stages, including translation initiation, elongation, and
termination. It is well accepted that protein synthesis is primarily
regulated during the translation initiation stage, where ribosomal
subunits are recruited to the mRNA facilitated by the eukaryotic
initiation factor 4F (eIF4F) (1–3). eIF4F is a heterotrimeric com-
plex composed of an mRNA cap-binding protein (eIF4E), a scaf-
folding protein (eIF4G), and an ATP-dependent RNA helicase
(eIF4A). eIF4E binds to the mRNA 5′ cap structure and facilitates
the recruitment of mRNA to ribosomes (4, 5). eIF4Gbridges eIF4E
and eIF4A, and further stabilizes the cap-eIF4E interaction (6).
eIF4A acts as a RNA helicase to remodel 5′-proximal secondary
structure to facilitate 40S ribosome recruitment (7, 8).
Formation of eIF4F, one of the rate-limiting steps during ini-
tiation, is aberrantly regulated during cellular transformation
and tumorigenesis (3, 9). Overexpression of eIF4E or eIF4G in-
duces cellular transformation in different cell-based experiments
(10–13). Increased signaling flux through mitogenic signaling
pathways converging on mTORC1 promotes eIF4F assembly and
activity. mTORC1 activation leads to phosphorylation of eIF4E-
binding proteins (4EBPs) and programmed cell death 4 (PDCD4),
two intrinsic inhibitory binding partners of eIF4E and eIF4A, re-
spectively, thus liberating eIF4E and eIF4A to engage in the
binding of eIF4G (14, 15). Ras pathway signaling through Erk
stimulates the MNK kinases to phosphorylate eIF4E at serine
209. This phosphorylation event stimulates translation of a sub-
set of mRNAs important for cell growth, proliferation, and
metastasis, leading to enhanced cellular transformation both in
cultured cells and in vivo (16). Disruption of eIF4F activity or
assembly by either genetic approaches or small-molecule inhib-
itors potently impairs tumor formation in mouse models (17).
Despite these studies, the molecular mechanisms that regulate
eIF4F activity/assembly have not been fully defined and are re-
quired to improve our current understanding of the relationship
between translation regulation and cellular transformation.
O-linked β-N-acetylglucosamine (O-GlcNAc) is a prevalent
posttranslational modification of nuclear and cytosolic proteins
(18). Cycling of O-GlcNAc on proteins is controlled by the action
of a set of enzymes in cells. O-GlcNAc transferase (OGT) cata-
lyzes the addition of GlcNAc to proteins, while O-GlcNAc hy-
drolase (OGA) is responsible for removal of the GlcNAc moiety.
Research has identified hundreds of intracellular proteins
containing the modification. Increasing evidence has shown
that O-GlcNAcylation regulates various important biological
processes, including transcription, stem-cell differentiation,
signal transduction, cell cycle progression, and metabolic
reprogramming (19, 20). Recently, a few studies have reported
that proteins involved in the translation process and ribosomal
biogenesis are O-GlcNAcylated, raising an intriguing possibility
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that O-GlcNAcylation regulates protein synthesis (21–23). For
example, Datta et al. (24, 25) showed that O-GlcNAcylation of
p67 protected the eukaryotic initiation factor 2α (eIF2α) from
phosphorylation by eIF2 kinase, leading to enhanced protein
synthesis. Duan et al. (22) demonstrated that O-GlcNAcylation of
a ribosomal protein RACK1 induced protein synthesis and was
required for tumorigenesis in liver cancer. Despite these elegant
studies, the understanding of the mechanistic link between O-
GlcNAcylation and protein synthesis still remains incomplete.
Here, we demonstrate that O-GlcNAcylation regulates protein
synthesis by modifying the core translation factors eIF4A and
eIF4G, respectively. Mechanistically, site-specific O-GlcNAcylation
of eIF4A disrupts eIF4F assembly by perturbing its interaction with
eIF4G. In addition, O-GlcNAcylation inhibits the duplex unwinding
activity of eIF4A. Collectively, eIF4A glycosylation impaired protein
synthesis, and reduced cell proliferation. In contrast, site-specific
O-GlcNAcylation of eIF4G at its N terminus promotes its in-
teraction with poly(A)-binding protein (PABP) and poly(A)
RNA, with no obvious effect on the interaction with eIF4A or
eIF4E. Depletion of eIF4G O-GlcNAcylation results in inhibition
of protein synthesis and cell proliferation. In addition, the differ-
ential glycosylation of eIF4A and eIF4G appears to be regulated in
the eIF4F complex to fine tune protein synthesis. Thus, our study
reveals a molecular mechanism for regulating protein synthesis
in cells.
Results
Core Components of the Translation Initiation Complex Are Modified
by O-GlcNAc. To investigate whether OGT physically associates
with the translation initiation complex eIF4F in cells, we per-
formed pull-down assays using m7GDP affinity beads. Consistent
with previous studies, eIF4F was efficiently isolated from
293T cell lysates (Fig. 1A) (26). OGT was readily detected in the
pull-down mixture, indicating that OGT was associated with the
eIF4F (Fig. 1A). Next we determined which protein components
in the eIF4F were O-GlcNAcylated using a well-established
chemoenzymatic labeling method (SI Appendix, Fig. S1) (23).
We enzymatically labeled O-GlcNAcylated proteins in 293T cell
lysates with an azido-N-acetylgalactosamine sugar (GalNAz).
Labeled proteins were then biotinylated via Cu(I)-mediated [3+2]
azide-alkyne cycloaddition chemistry and captured on streptavidin-
agarose beads. Subsequent elution fractions from the beads were
immunoblotted with specific antibodies against eIF4A, eIF4E,
and eIF4G, respectively. Strong signals were readily detected with
eIF4A and eIF4G antibodies, but not with the eIF4E antibody,
suggesting that eIF4A and eIF4G were modified by O-GlcNAc
(Fig. 1B). This is consistent with our previous proteomic studies in
which eIF4A and eIF4G were identified as putative O-GlcNAcylated
proteins (27). Quantification of the glycosylated protein fractions
versus total proteins yielded an estimated basal level of glyco-
sylation stoichiometries of 15 ± 5% and 7 ± 3% for eIF4A and
eIF4G, respectively. Studies have shown that two other critical
translation initiation factors, eIF4B and eIF4H, are strongly as-
sociated with the eIF4F complex during translation initiation
(28). Therefore, we tested whether eIF4B and eIF4H were O-
GlcNAcylated in cells. Results showed a weak signal for eIF4B,
and no detectable signal for eIF4H, suggesting that eIF4B was
weakly modified by O-GlcNAc, while eIF4H did not possess O-
GlcNAcylation (Fig. 1B). Since OGT is physically associated
with the eIF4F, it would preferentially modify eIF4A and eIF4G
as subunits of the complex. As expected, in the fraction pulled
down with m7GDP beads eIF4A and eIF4G displayed higher
level of glycosylation compared with eIF4A and eIF4G from the
cell lysate fraction (Fig. 1C). In mammalian cells, both eIF4A
and eIF4G have two major isoforms, namely eIF4AI, eIF4AII,
eIF4GI, and eIF4GII, respectively (29, 30). Previous studies have
demonstrated that eIF4AI and eIF4GI are expressed more abun-
dantly than the other isoforms in cells (31). Using isoform-specific
siRNAs, we demonstrated that depletion of isoform eIF4AI or
eIF4GI strongly inhibited cell proliferation, while depletion of
isoform eIF4AII or eIF4GII had a very modest effect on cell
proliferation compared with the parental cells (SI Appendix, Fig.
S2), suggesting that isoforms eIF4AI and eIF4GI are more func-
tionally important. Thus, we focused on isoforms eIF4AI and
eIF4GI in the following studies.
To investigate whether O-GlcNAcylation of eIF4AI and eIF4GI
is dynamically regulated in cells, we subjected cells to different
treatments and analyzed the glycosylation levels. Overexpression
of OGT increased, while OGT inhibition decreased O-GlcNAcylation
on both eIF4AI and eIF4GI proteins (Fig. 1D). Consistently,
OGA overexpression decreased, while OGA inhibition increased
O-GlcNAcylation levels (Fig. 1D). Varying concentrations of the
two major nutrients (glucose and glutamine) in the culture me-
dium resulted in altered glycosylation levels (Fig. 1D). Thus, O-
GlcNAcylation of eIF4AI and eIF4GI is dynamically regulated
in cells.
We further examined whether O-GlcNAcylation of eIF4AI
and eIF4GI occurs across different malignant and noncancerous
cells. Glycosylation of eIF4AI and eIF4GI was detected in a wide
range of malignant cell lines, to varied degrees (Fig. 1 E and F).
Notably, the glycosylation level of eIF4AI in noncancerous cells
was significantly higher than that in malignant cells of the same
cell type, as shown in ovarian, stomach, and liver cell lines (Fig.
1E). In contrast, the glycosylation level of eIF4GI in noncancerous
cells was significantly lower than that in malignant cells of the
same cell type, as shown in ovarian, stomach, and breast cell lines
(Fig. 1F). It appears that cancer cells down-regulate eIF4AI gly-
cosylation, but up-regulate eIF4GI glycosylation.
To correlate eIF4A and eIF4G glycosylation with clinical
disease progression, we examined human tumor tissue samples
and normal tissue samples (SI Appendix, Fig. S3). Consistent with
the results observed from the cell lines, eIF4A O-GlcNAcylation
levels were decreased in ovarian tumor tissues compared with that
in normal tissues. On the other hand, the majority of breast tumor
tissues exhibited relatively higher levels of eIF4G glycosylation
compared with normal tissues. The differences in glycosylation
patterns observed in both cell lines and tissues between eIF4AI
and eIF4GI suggest a differential role for O-GlcNAcylation in
regulating their biological functions in vivo.
O-GlcNAcylation of eIF4AI Disrupts Assembly of the eIF4F. To in-
vestigate the role of O-GlcNAcylation on eIF4AI, we first deter-
mined its glycosylation site(s). Flag-tagged eIF4AIproteins were
expressed in 293T cells. After immunoprecipitation of Flag-tagged
eIF4AI and in-gel trypsin digestion, peptides were subjected to mass
spectrometry analysis. Glycosylation sites were mapped to serine 322
and serine 323 (SI Appendix, Fig. S4). Single site mutations (S322A/
Y or S323A/Y) only modestly reduced the level of glycosylation
compared with the wild type (Fig. 2A). Double site mutations (S322/
S323A or S322/S323Y) nearly abolished the glycosylation signals,
indicating that Ser322 and Ser323 are the major glycosylation sites
on eIF4AI (Fig. 2A).
Sequence comparison analysis showed that Ser322 and Ser323
were conserved residues in homolog eIF4A proteins across dif-
ferent species, indicating a possible functional role for these
residues (Fig. 2B). Three-dimensional structures have been de-
termined for a few eIF4A proteins from different species (32).
Structural analysis revealed that the glycosylation sites resided in
a loop structure connecting an alpha helix and a beta sheet (Fig.
2C). Notably, a protein complex structure determined with yeast
eIF4AI and eIF4GI revealed that the conserved sequence
(SGSSR) containing the glycosylation sites resided at the interface
where eIF4AI and eIF4GI interacted (Fig. 2C) (33). Although the
internal serine residues in the SGSSR corresponding to the glyco-
sylation sites did not form any direct hydrogen bonds with residues
in eIF4GI, a bulky GlcNAc modification would very likely cause
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substantial perturbations in the protein–protein interaction. To
verify this on human eIF4AI, we generated a S322/S323A mutant (a
mimetic of deglycosylation) and a S322/S323Y mutant (a mimetic of
bulky glycosylation). A tyrosine residue has been demonstrated in a
recent report to be a proper mimetic of O-GlcNAcylation due to its
bulky size (34). Flag-tagged eIF4AI WT or mutants were stably
transfected in 293T cells. Immunoprecipitation was carried out using
anti-Flag M2 beads, and further immunoblotted with an antibody
against eIF4GI. Results showed that comparable amounts of
eIF4GI were pulled down in WT and S322/S323A expressing
cells, while significantly less amounts of eIF4GI were detected
in S322/S323Y expressing cells, consistent with the prediction
that O-GlcNAcylation disrupted the eIF4AI and eIF4GI interaction
(Fig. 2D). As a further verification, we increased O-GlcNAcylation
in the WT eIF4AI expressing cells by Thiamet G (TMG) treatment
(inhibition of OGA) or OGT overexpression, and immunoblotted
eIF4GI after M2 bead pull-down. We observed that increasing
eIF4AI glycosylation led to decreased amounts of eIF4GI during
the pull-down, suggesting a loss of interaction between eIF4AI
and eIF4GI (Fig. 2E). TMG treatment and OGT overexpression
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Fig. 1. Core components of the translation initiation complex are modified by O-GlcNAc. (A) OGT associates with the translation initiation complex eIF4F in
cells. The eIF4F complex was isolated from 293T cell lysates using m7GDP affinity beads. After elution from the beads, Western blot analysis was performed
with antibodies against eIF4A, eIF4E, eIF4G, or OGT. The control experiment (Cont.) was performed similarly with protein G agarose beads. (B) Key com-
ponents (eIF4A and eIF4G) of the translation initiation complex are modified by O-GlcNAc. The isolation and detection of specific O-GlcNAcylated proteins in
cell lysates are described in SI Appendix. As input, 10% of total protein was loaded. (C) O-GlcNAcylation preferentially occurs on eIF4AI and eIF4GI as subunits
of the eIF4F. The eIF4F was pulled down using m7GDP beads, and the glycosylation of eIF4AI and eIF4GI was analyzed. (D) O-GlcNAcylation of eIF4AI and
eIF4GI is dynamically regulated in cells. HEK293T cells were subjected to different treatments (Cont., Control; Glc, Glucose; Glut, Glutamine; OGA, OGA
overexpression; OGAi, OGA inhibition with ThiaMet G; OGT, OGT overexpression; OGTi: OGT inhibition with ST045849), and the O-GlcNAcylation levels of
eIF4AI and eIF4GI were analyzed. Quantification of protein levels was indicated. As input, 8% of total protein was loaded. (E) Glycosylation of eIF4AI was up-
regulated in noncancerous cells (IOSE80, GES1, and LO2) compared with malignant cells, as shown in ovarian, stomach, and liver cell lines. Quantification of
protein levels was indicated. (F) Glycosylation of eIF4GI was down-regulated in noncancerous cells (IOSE80, GES1, and MCF-10A) compared with malignant
cells, as shown in ovarian, stomach, and breast cell lines. Quantification of protein levels was indicated.
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Fig. 2. O-GlcNAcylation of eIF4AI disrupts assembly of the eIF4F. (A) S322 and S323 are the major glycosylation sites of eIF4AI. Site-specific mutations were
generated: single mutants (S322A, S322Y, S323A, S323Y) and double mutants (S322/S323A, S322/S323Y). Glycosylation levels of these mutants were analyzed
using the chemoenzymatic method and compared with the WT protein. Quantification of protein levels was indicated. As input, 10% of total protein was
loaded. (B) The glycosylation sites of eIF4AI are conserved across different species. Human (NP_001191439.1), Saccharomyces cerevisiae (NP_012985.3),
Musmusculus (NP_001152847.1), Rattusnorvegicus (NP_001093628.1), Drosophila melanogaster (NP_001245907.1). (C) The glycosylation sites of eIF4AI reside
at the interaction interface between eIF4AI and eIF4GI. The crystal structure of the yeast eIF4A-eIF4G complex was obtained from the Protein Data Bank
databank (2VSO). (D) The effect of eIF4AI glycosylation site mutations on protein–protein interactions. Flag-tagged WT, S322/323A, or S322/323Y eIF4AI was
stably expressed in 293T cells. Immunoprecipitation was carried out using anti-Flag M2 beads, and the pull-down complex was immunoblotted with the
indicated antibodies. Quantification of protein levels was indicated. As input, 5% of total protein was loaded. (E and F) Increasing eIF4AI glycosylation
reduces the interaction with eIF4GI. HEK293T cells expressing Flag-tagged WT or S322/323A eIF4AI were subjected to TMG treatment or OGT expression.
Immunoprecipitation was carried out using anti-Flag M2 beads, and the eluent was immunoblotted with eIF4GI antibodies. Quantification of protein levels
was indicated. As input, 5% of total protein was loaded. (G–I) The interaction of eIF4AI and eIF4GI is increased in the presence of low glucose concentration.
Flag-tagged WT eIF4AI, S322/323A eIF4AI, or Myc-tagged eIF4GI was individually or coexpressed in 293T cells in the presence of high- (HGlc, 25 mM) or low
(LGlc, 5 mM) glucose concentrations. Immunoprecipitation was carried out using anti-Flag M2 beads, and the eluent was immunoblotted with the indicated
antibodies. Quantification of protein levels was indicated. As input, 5% of total protein was loaded. (J) The interaction of endogenous eIF4AI and eIF4GI is
increased in the presence of low glucose concentration. Ovarian cancer cell line A2780 was cultured in the presence of high- (HGlc, 25 mM) or low (LGlc, 5 mM)
glucose concentrations. Immunoprecipitation was carried out using an eIF4AI antibody, and the eluent was immunoblotted with an eIF4GI antibody.
Quantification of protein levels was indicated. As input, 10% of total protein was loaded.
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induced eIF4AI glycosylation levels by about 3.1- and 4.3-fold,
respectively (SI Appendix, Fig. S5A). Given the basal glycosylation
level of eIF4AI around 15%, the glycosylation levels upon TMG
treatment or OGT overexpression are estimated to be 45 and
64%, respectively. In contrast, in the S322/S323A mutant expressing
cells, TMG treatment or OGT overexpression appeared to have
no effect on the detection signals of eIF4GI (Fig. 2F). We fur-
ther cultured cells in different concentrations of glucose, and
consistently observed that in WT but not S322/S323A mutant
expressing cells, a low glucose level enhanced the interaction,
while a high glucose level reduced the interaction (Fig. 2G–I and
SI Appendix, Fig. S5B). To verify the effect of O-GlcNAcylation
on endogenous proteins, ovarian cancer cell line A2780 was
cultured in the presence of 5- or 25 mM glucose. The interaction
between eIF4AI and eIF4G was higher in 5 mM glucose con-
centration (Fig. 2J). Collectively, our results showed that O-
GlcNAcylation of eIF4AI inhibited its interaction with eIF4GI.
Although eIF4E does not directly interact with eIF4AI, it is
known to associate with eIF4AI in the complex through an in-
teraction with eIF4GI. Consistently, the association of eIF4E
with eIF4AI followed the same trend as that observed between
eIF4AI and eIF4GI (Fig. 2D). O-GlcNAcylation on eIF4AI did
not appear to affect its interaction with eIF4B or PDCD4, an
intrinsic inhibitor of eIF4AI (Fig. 2D).
O-GlcNAcylation of eIF4AI Inhibits Its Helicase Activity and Impairs
Protein Synthesis and Cell Proliferation. To understand the im-
pact of O-GlcNAcylation on eIF4AI function, we investigated
the duplex unwinding activity (helicase activity) of different
eIF4AI variants. Similar helicase activities were observed with
WT and S322/S323A mutant proteins (Fig. 3A). However, the
S322/S323Y mutant showed a significantly reduced helicase ac-
tivity (Fig. 3A). To further verify the effect of O-GlcNAcylation,
we obtained bacterially expressed His-tagged eIF4AI as a non-
glycosylated protein, and purified 293T-expressed Flag-tagged
eIF4AI (with TMG treatment to enhance glycosylation) as an O-
GlcNAcylated protein (SI Appendix, Fig. S6). We then compared
the duplex unwinding activity between these two forms of pro-
teins. Consistent with the mutagenesis studies, O-GlcNAcylated
eIF4AI exhibited lower duplex unwinding activity compared with
the nonglycosylated counterpart (Fig. 3B).
As O-GlcNAcylation of eIF4AI appears to disrupt the assembly
of eIF4F and inhibit the helicase activity, we speculated that cel-
lular protein synthesis would be affected. We first analyzed the in
vitro translation activity using the rabbit reticulocyte lysate system.
Addition of the S322/S323Y mutant eIF4AI inhibited the trans-
lation efficiency in a dose-dependent manner, while addition of
the S322/S323A mutant did not show detectable inhibition (SI
Appendix, Fig. S7A). Consistently, addition of the TMG-treated
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Fig. 3. O-GlcNAcylation of eIF4AI negatively regulates its activity and impairs protein synthesis. (A) Determination of the duplex unwinding activity of WT,
S322/S323A, and S322/S323Y eIF4AI, as described in SI Appendix. A control experiment was performed in the absence of eIF4AI (Cont.). (B) Comparison of the
duplex unwinding activity between bacterially expressed (Bact.) eIF4AI and 293T-expressed (Euk.) eIF4AI. Coomassie Brilliant Blue staining was performed to
verify protein expression. A control experiment was performed in the absence of eIF4AI (Cont.). (C) Strategy for determination of nascent protein synthesis in
293T cells stably expressing WT, S322/S323A, or S322/S323Y eIF4AI. Cells were metabolically labeled with HPG, a synthetic analog of methionine containing an
alkyne functionality, and the synthesized proteins were detected using a bioorthogonal chemical ligation with azido-containing Alexa Fluor 488. Fluorescence
signal intensity was normalized with respect to the cell numbers and represented the amount of synthesized protein pools. (D) Quantification of nascent
protein synthesis rates in 293T cells stably expressing WT, S322/S323A, or S322/S323Y eIF4AI. A control experiment was performed using cells with depletion of
eIF4AI (Kd). (E) Polysome profiling analysis of 293T cells stably expressing WT, S322/S323A, or S322/S323Y eIF4AI.
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eIF4AI reduced the translation activity compared with addition of
nontreated eIF4AI (SI Appendix, Fig. S7B). Thus, glycosylation of
eIF4AI inhibited in vitro translation. To determine the effect on
protein synthesis in vivo, we further analyzed the rate of nascent
protein synthesis in 293T cells stably expressing WT and mutant
eIF4AI. Cells were metabolically labeled with L-homopropargylglycine
(HPG), a synthetic analog of methionine containing an alkyne
functionality, and the synthesized proteins were detected using a
bioorthogonal chemical ligation with azido-containing Alexa
Fluor 488 (Fig. 3C) (35). Fluorescent signal intensity was normalized
with respect to cell numbers and represented the amount of syn-
thesized protein pools. In agreement with the results obtained from
the in vitro translation system, cells expressing the WT or S322/
S323A mutant eIF4AI displayed similar fluorescent signal in-
tensity, while cells expressing the S322/S323Y mutant displayed
markedly reduced signal intensity (Fig. 3D). As another confir-
mation, we performed the traditional [35S]-methionine metabolic
incorporation assay (SI Appendix, Fig. S8). Thus, O-GlcNAcylation
of eIF4AI appears to impair translation both in vitro and in vivo. In
addition, polysome profiling analysis showed that the S322/S323Y
mutant expressing cells displayed reduced amounts of polysomes
compared with the WT or S322/S323A mutant expressing cells (Fig.
3E), suggesting ineffective translation in the S322/S323Y mutant
expressing cells.
We further validated the function of eIF4AI glycosylation using
A2780 ovarian cancer cells that stably expressed Flag-tagged WT
or mutant eIF4AI with simultaneous depletion of endogenous
eIF4AI (SI Appendix, Fig. S9A). Consistent with the effect on
nascent protein synthesis, cells expressing the WT or S322/
S323A mutant showed comparable rates of cell proliferation,
while cells expressing the S322/S323Y mutant showed markedly
reduced cell proliferation rate (SI Appendix, Fig. S9B). Soft agar
colony formation assays also demonstrated that cells expressing
the S322/S323Y mutant showed significantly reduced ability to
form colonies compared with cells expressing the WT or S322/
S323A mutant (SI Appendix, Fig. S9C). Collectively, O-GlcNAcylation
of eIF4AI inhibits its helicase activity, and impairs protein syn-
thesis and cell proliferation.
O-GlcNAcylation of eIF4GI Promotes Assembly of mRNP During the
Initiation. To investigate the role of O-GlcNAcylation on eIF4GI,
we determined its glycosylation site(s). In our previous study,
using mass spectrometry we mapped the glycosylation sites to a
peptide 56-AQPPSSAASR-65 (27). Mutation of a single residue,
Ser60 or Ser64, to alanine only modestly reduced eIF4GI gly-
cosylation in cells, while mutation of Ser61 to alanine markedly
reduced eIF4GI glycosylation (Fig. 4A). Furthermore, simulta-
neous mutations of all three serine residues to alanine led to a
comparable reduction of glycosylation signals compared with the
S61A mutant (Fig. 4A). These results suggest that Ser61 is the
major glycosylation site in eIF4GI. Thus, the S61A mutant was
used in subsequent studies to analyze the role of glycosylation
on eIF4GI.
We investigated whether glycosylation of eIF4GI affected its
interaction with known binding proteins. Flag-tagged eIF4GI
WT or S61A mutant was stably expressed in 293T cells. Immu-
noprecipitation was carried out using anti-Flag M2 beads, and
the pull-down mixture was further immunoblotted with antibodies
against eIF4AI or eIF4E. We observed that comparable amounts of
eIF4AI and eIF4E were pulled down in WT and mutant eIF4GI
expressing cells, indicating that O-GlcNAcylation on eIF4GI did
not affect its interaction with these subunits (Fig. 4B). Furthermore,
cellular treatment with TMG had no obvious effect on the de-
tection signals of eIF4AI or eIF4E. Previous studies have found
that eIF4E interacts with the N-terminal domain and eIF4AI in-
teracts with the middle and C-terminal domain of eIF4GI, quite
remote from its O-GlcNAcylation sites, which are located near the
N terminus (36). These observations lend support to the notion that
unlike eIF4AI, eIF4GI glycosylation does not seem to interfere
with the assembly of eIF4F.
In eukaryotes, the association of PABP and eIF4GI is critical
for efficient mRNA translation. Previous studies have mapped
their interaction site to the N terminus of eIF4GI (29, 37). Thus,
we wanted to investigate whether O-GlcNAcylation might affect
the interaction between eIF4GI and PABP. We found that signifi-
cantly more PABP was pulled down in Flag-eIF4GI expressing cells
treated with TMG compared with cells without TMG treatment,
suggesting that increasing O-GlcNAcylation might enhance the in-
teraction between eIF4GI and PABP (Fig. 4B). Expectedly, in the
eIF4GI S61A mutant expressing cells, a markedly reduced amount
of PABP was pulled down compared with the WT expressing cells.
Treatment of the mutant expressing cells with TMG did not have
any obvious effect on the PABP signal (Fig. 4B).
To verify further the interaction between eIF4GI and PABP,
Myc-tagged PABP was generated and cotransfected in 293T cells
with Flag-tagged eIF4GI. Significantly lower amounts of PABP
were pulled down in the eIF4GI S61A mutant expressing cells
with anti-Flag antibodies compared with the WT expressing cells,
consistent with the data shown above (Fig. 4C). Reversal pull-
down experiments using anti-Myc antibodies also showed that
lower amounts of eIF4GI S61A were coimmunoprecipitated
compared with eIF4GI WT (SI Appendix, Fig. S10). To investi-
gate whether the O-GlcNAcylation effect on eIF4GI/PABP in-
teraction occurs with endogenous proteins, we cultured 293T
cells in the presence of low- (5 mM) or high (25 mM) concentrations
of glucose, carried out immunoprecipitation using anti-eIF4GI an-
tibodies, and immunoblotted with anti-PABP antibodies. Con-
sistently, significantly more PABP was detected in cells grown
under high glucose concentrations (Fig. 4D). Similar experi-
ments were also carried out using the breast cancer cell line
MCF-7, in which a similar result was obtained (Fig. 4E). Taken
together, O-GlcNAcylation of eIF4GI enhances its interaction
with PABP in cells.
Several lines of evidence have demonstrated that the eIF4GI/
PABP interaction is important for the stabilization of eIF4GI
binding to mRNA during translation initiation (38). Indeed, one
of the RNA binding domains in eIF4GI has been mapped to the
extreme N terminus of eIF4GI (amino acids 1–82), which in-
cludes the O-GlcNAcylation sites (39). Thus, we speculated that
O-GlcNAcylation of eIF4GI is important for the interaction with
mRNA. To test this hypothesis, we generated a bacterially expressed,
recombinant GST fusion protein containing the N-terminal aa 2–
300 of WT eIF4GI and the corresponding S61Aand S61Y mu-
tants. We then analyzed the effects on RNA-binding activity by
measuring the increase in fluorescence anisotropy of fluorescently
labeled RNA poly(A) 50-mer upon binding to eIF4GI WT and
mutant proteins. In addition, eIF4GI protein lacking the N-terminal
RNA binding domain (aa 1–82) was included as a negative control.
The results showed that the dissociation constant (Kd) for the WT
eIF4GI fusion protein was 0.41 μM, fairly similar to that reported
before (37). The S61Y mutant protein showed a slight increase in
binding affinity, with a Kd of 0.32 μM. In contrast, the S61A mutant
protein showed a nearly sixfold reduction in binding affinity, with a
Kd of 2.38 μM. The negative control completely lacked the ability to
bind RNA as expected (Fig. 4F). Thus, these results appear to
suggest that O-GlcNAcylation of eIF4GI may promote the assembly
of mRNP by enhancing the interaction with PABP and the binding
of RNA to the initiation complex.
To investigate the function of eIF4GI O-GlcNAcylation in cells,
we generated eIF4GI S61A knock-in MCF-7 cell lines using
CRISPR-Cas9 gene editing technology. We also generated a mu-
tant cell line by knocking out the splicing isoforms containing the
glycosylation sites to serve as a positive control (SI Appendix, Fig.
S11). We verified that O-GlcNAcylation levels of eIF4GI in these
two mutant cell lines were substantially decreased compared with
the parental cells (Fig. 5A). Immunoprecipitation with anti-eIF4GI
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antibodies showed decreased signals of PABP in the mutant cell
lines. Treatment with TMG increased the amounts of PABP
during pull-down in the parental cells, but had no obvious effect
in the S61A knock-in cells (Fig. 5B). These results are consistent
with the data obtained in 293T cells. Next, we investigated
whether eIF4GI O-GlcNAcylation affected nascent protein
synthesis. Metabolic labeling experiments with HPG consistently
showed that the mutant cells exhibited a significantly lower rate
of protein synthesis compared with the parental cells (Fig. 5C).
In agreement with these results, the mutant cells also displayed
lower cell proliferation in vitro and reduced ability to form colo-
nies in the soft agar colony formation assay (Fig. 5D and E). Thus,
these results demonstrate that O-GlcNAcylation of eIF4GI posi-
tively regulates protein synthesis and cell proliferation.
Discussion
Protein synthesis is a tightly regulated process and subjected to
various modes of regulation. Aberrant activity of protein syn-
thesis has been shown to contribute to various diseases including
cancer. Protein synthesis is primarily regulated at the stage of
translation initiation, in which the assembly of a functional eIF4F
complex is one of the rate-limiting steps. The eIF4F is regulated
in cells through different mechanisms, including transcriptional
control of MYC, intrinsic protein–protein interactions exerted by
4EBPs and PDCD4, and phosphorylation of the eIF4E subunit.
Positioned downstream of well-established signaling pathways
(e.g., PI3K/AKT/mTOR, Ras/Erk, and MYC), eIF4F serves as a
key molecular mechanism linking growth factor signaling path-
ways with protein synthesis during cell growth and proliferation
A
C
D
F
E
B
Fig. 4. O-GlcNAcylation of eIF4GI promotes assembly of mRNP during translation initiation. (A) S61 is the major glycosylation site on eIF4GI. Single- (S60A,
S61A, and S64A) and triple (S60/61/64A) mutations in eIF4GI were generated. Glycosylation levels of WT and mutant eIF4GI were analyzed by the chemo-
enzymatic method as described above. Quantification of protein levels was indicated. As input, 8% of total protein was loaded. (B and C) S61 glycosylation of
eIF4GI enhances its interaction with PABP. Flag-tagged WT, S61A eIF4GI, or Myc-tagged PABP was individually or coexpressed in 293T cells in the presence or
absence of TMG. Immunoprecipitation was carried out using anti-Flag M2 beads, and the eluent was immunoblotted with the indicated antibodies.
Quantification of protein levels was indicated. As input, 5% of total protein was loaded. (D and E) The interaction of endogenous eIF4GI and PABP is in-
creased in the presence of high glucose concentration in both 293T cells (D) and MCF-7 cells (E). Quantification of protein levels was indicated. As input, 5% of
total protein was loaded. (F) eIF4GI glycosylation promotes the interaction with poly(A) mRNA. RNA-binding activity was measured by the increase in
fluorescence anisotropy of fluorescently labeled RNA poly(A) 50-mer upon binding to eIF4GI WT, S61A, or S61Y mutant proteins. eIF4GI protein lacking the N-
terminal RNA binding domain (aa 1–82) was included as a negative control (Cont.).
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(40, 41). Despite the critical role of eIF4F in protein synthesis
and cellular transformation, the understanding how eIF4F assembly/
activity is differentially regulated in cells is far from complete. In
this study, we identify O-GlcNAcylation as a mechanism for
regulating eIF4F assembly and activity. We show that OGT as-
sociates with eIF4F, and directly modifies subunits eIF4A and
eIF4G to modulate protein–protein interactions and the helicase
activity of eIF4A. The site-specific glycosylation of eIF4A and
eIF4G is shown to influence protein translation both in vitro and
in vivo. Thus, our results add a dimension of complexity to the
translational control of cellular proteins.
Cellular eIF4AI is the most abundant initiation factor and
exists as two forms—free cytosolic protein and part of the eIF4F
complex, with the majority being the free form. Even though free
eIF4A proteins may not directly participate in translation initia-
tion, studies have shown that they can exchange and incorporate
into eIF4F (17, 28). How does glycosylation of eIF4A exert the
inhibitory effect on protein translation? Firstly, our results show
that glycosylation of eIF4A suppresses the helicase activity, an
essential enzymatic activity for efficient translation initiation.
Secondly, glycosylation of eIF4A at its C-terminal domain reduces
the interaction with eIF4G, and possibly destabilizes the forma-
tion of a functional eIF4F. Glycosylated eIF4A can compete with
free eIF4A to incorporate into eIF4F, as addition of the S322/
S323Y mutant or glycosylated eIF4A in the translation system in
the presence of WT eIF4A caused substantial translation inhibi-
tion (SI Appendix, Fig. S7). OGT is physically associated with
eIF4F, and readily directs O-GlcNAcylation to eIF4A in the
complex. The eIF4A in the complex is much less abundant than
free eIF4A, and thus, a better target for inhibition of translation
initiation. To support this, we pulled down eIF4F using m7GDP
beads and compared the O-GlcNAcylation level between the two
forms of eIF4A. We showed that eIF4A in the complex displayed
more than twofold higher level of glycosylation compared with
free eIF4A (Fig. 1C). In addition, when we used a cleavable cross-
linker (sulfo-NHS-SS-diazirine) to capture the transient and weak
interactions in cells and pulled down eIF4F with m7GDP, we
found that glycosylation level of eIF4A was even higher compared
with the samples without capture, suggesting that glycosylated
eIF4A is loosely bound and tends to dissociate from the com-
plex (SI Appendix, Fig. S12). Thirdly, even though the basal
level of glycosylation on eIF4A in cells is about 15%, the gly-
cosylation level can reach more than 60% upon cellular treat-
ments, suggesting that eIF4A glycosylation is highly dynamic
and responsive to environmental stimuli. This is particularly
important given the various adaptations of protein synthesis in
response to many different stresses and physiological conditions.
Glycosylation may serve as a mechanism to fine-tune protein
synthesis in cells.
Increasing evidence has demonstrated the pivotal role of O-
GlcNAcylation in regulating a diverse set of proteins that func-
tion in transcription, insulin signaling, and cellular metabolism
(42–44). Site-specific O-GlcNAcylation has been shown to govern
the biological functions of the corresponding protein substrates
(20, 45). In our study, O-GlcNAcylation of eIF4A on Ser322/
323 disrupted the assembly of the eIF4F complex, inhibited its
helicase activity, and led to impaired protein synthesis. In contrast,
O-GlcNAcylation of eIF4G on Ser61 promoted the assembly of
mRNP by enhancing the interaction with PABP and poly(A)-
mRNA, thus positively regulating protein synthesis. It is quite
unexpected and yet intriguing that O-GlcNAcylation plays a
seemingly opposing role in regulating eIF4A and eIF4G func-
tions. Based on our experimental observations, it appears that
cancer cells selectively down-regulate eIF4A glycosylation but
up-regulate eIF4G glycosylation. This differential glycosylation
pattern was observed in both cell lines and tissue samples,
suggesting a complex regulation of protein synthesis in vivo. We
also demonstrate that during cell cycle progression, the glyco-
sylation pattern between eIF4A and eIF4G displays an opposite
trend (SI Appendix, Fig. S13). After m7GDP beads pull-down,
the result showed that glycosylation level of eIF4A is the highest
at the S phase, and the lowest at the G2M/G1 phase. In contrast,
eIF4G glycosylation level is the lowest at the S phase, and the
highest at the G2M/G1 phase (SI Appendix, Fig. S13 B and C).
Furthermore, the trend of eIF4A glycosylation was less pro-
nounced when the whole cell lysate was directly analyzed (without
m7GDP beads pull-down), suggesting that the differential glyco-
sylation is regulated at the level of eIF4F complex.
A
C D E
B
Fig. 5. O-GlcNAcylation of eIF4GI positively regulates protein synthesis and cell proliferation. (A) Significant decrease of eIF4GI glycosylation in eIF4GI S61A
knock-in and isoform knockout (KO) MCF-7 cells, compared with the parental cells. As input, 5% of total protein was loaded as input. (B) The interaction
between eIF4GI and PABP is increased in MCF-7 parental cells but not in MCF-7 (eIF4GI S61A knock-in) cells upon TMG treatment. Immunoprecipitation was
performed using an eIF4GI antibody, and the eluent immunoblotted with a PABP antibody. Quantification of protein levels was indicated. As input, 5% of
total protein was loaded. (C–E) Depletion of eIF4GI glycosylation in MCF-7 cells reduces nascent protein synthesis (C), cell proliferation (D), and soft agar
colony formation (E). Error bars denote SEM. Statistical analysis was performed by Student’s t test (*P < 0.05, **P < 0.01).
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As OGT is the sole enzyme responsible for glycosylation of
both eIF4A and eIF4G in cells, another intriguing question is,
how would OGT achieve differential targeting and glycosylation
of these two proteins within the same complex? Different mecha-
nisms have been proposed to understand the activity regulation and
substrate specificity of OGT, which is a topic of active research in
recent years (46, 47). OGT activity is regulated by various factors,
including transcription, posttranslational modifications, and sugar
nucleotide (UDP-GlcNAc) concentration (48, 49). OGT substrate
specificity has been proposed to occur through protein–protein
interactions via its N-terminal tetratricopeptide domains (50).
Given the complex regulation of OGT in cells, it is not surprising
that OGT expression level or activity did not always agree with the
glycosylation levels of individual proteins even within the same
complex. It is also worth noting that O-GlcNAcylation can occur at
different rates even at different sites within the same protein. For
example, O-GlcNAcylation of CREB is only induced at Ser40 in
response to neuronal activity; yet there are other sites in the protein
that are basally glycosylated (51). As an extension of this study, it
would be intriguing to investigate the molecular mechanism by
which OGT differentially targets and glycosylates eIF4A and eIF4G
under certain growth conditions or stresses.
Materials and Methods
Cell Culture and Reagents. Cell lines 293T, IOSE80, A2780, OVCAR-8, OVCAR-
10, SKOV-3, GES-1, MGC803, KATO3, HGC27, MCF7, MCF10A, MDA-MB-231,
LO2, HepG2, and Hep3B were all obtained from American Type Culture
Collection (ATCC) and cultured according to ATCC protocols. Among them,
IOSE80, GES-1, MCF10A, and LO2 are considered as noncancerous epithelia
cells derived from ovarian, stomach, breast, and liver tissues, respectively.
Antibodies used in this study were obtained from the following sources: anti-
O-GlcNAc antibody (RL2, clone 18B10.C7, 1:1,000; Thermo Scientific), anti-
eIF4AI antibody (1:1,000; Abcam), anti-eIF4B antibody (clone EP2299Y,
1:1,000; Abcam), anti-eIF4E antibody (clone Y448, 1:500; Abcam), anti-
PDCD4 antibody (1:650; Sigma-Aldrich), anti-eIF4GI antibody (clone D6A6,
1:1,000; Cell Signaling Technology), anti-PABP1 antibody (1:1,000; Sigma-Aldrich),
anti-Flag antibody (cloneM2, 1:5,000; Sigma-Aldrich), anti-Myc antibody (1:5,000;
Abmart), anti-GAPDH antibody (clone G6; Santa Cruz Biotechnology). Procedures
related to human subjects were approved by the Ethic Committee of Zhejiang
Cancer Hospital. The informed consent was obtained for each patient.
Chemoenzymatic Labeling and Biotinylation of O-GlcNAcylated Proteins. Cell
lysate (500 μg) was labeled according to the Click-iT O-GlcNAc Enzymatic
Labeling System protocol (Invitrogen), and conjugated with an alkyne–bi-
otin compound as per the Click-iT Protein Analysis Detection Kit protocol
(Invitrogen). Control experiments were carried out in parallel in the absence
of the labeling enzyme GalT or UDP-GalNAz. Biotinylated lysates were
precipitated using methanol and chloroform, and resolubilized in 1% SDS,
and neutralized with an equal volume of neutralization buffer (6% Nonidet P-
40, 100 mM Na2HPO4, 150 mM NaCl). Lysates were then incubated with
streptavidin resin (Pierce) with end-to-end rotation at 4 °C overnight. Resins
were then washed five times with 1 mL of low-salt buffer (100 mM Na2HPO4,
150 mMNaCl, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxycholate) and five
times with 1 mL of high-salt buffer (100 mM Na2HPO4, 500 mM NaCl, 0.2%
Triton X-100). Biotinylated proteins were eluted by boiling the resin in 50 mM
Tris·HCl pH 6.8, 2.5% SDS, 100 mM DTT, 10% glycerol, and 20 mM biotin for
10 min. Western blotting analysis was carried out with indicated antibodies.
Statistical Analysis. P values were calculated from Student’s paired t test
when comparing within groups and from Student’s unpaired t test when
comparing between groups. For those analyses where more than one t test
was applied to the same dataset, statistical analysis was performed by one-
way analysis of variance and Bonferroni comparison posttest. Bars in graphs
indicate mean ± SEM.
All other experimental methods are provided in SI Appendix.
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